EUVIMEDEUVIMED entdecken
Crossref

L26/P-761 Oral Linzagolix for ovulation suppression during controlled ovarian stimulation compared with standard injectable GnRH antagonists in IVF cycles: a retrospective matched case–control study

G. Grisafi, B. Bortolini, M. Molgora, R. Biancardi, L. Privitera, R. Villanacci, S. D’ Alessandro, E. Angelini, E. Papaleo

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von G. Grisafi und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Can oral linzagolix 200 mg be considered an effective strategy for ovulation suppression during controlled ovarian stimulation (COS) compared with standard injectable GnRH antagonists? Summary answer Oral linzagolix 200 mg was not associated with premature ovulation or premature progesterone elevation compared with standard injectable GnRH antagonists during COS. What is known already During controlled ovarian stimulation, prevention of premature ovulation relies on effective suppression of LH secretion, currently achieved using injectable GnRH antagonists. These agents provide reliable ovulation blockade and flexible cycle management but require daily subcutaneous administration and are associated with substantial treatment costs. Oral GnRH receptor antagonists induce immediate, competitive inhibition of pituitary GnRH receptors, resulting in suppression of LH secretion. Linzagolix is a potent oral GnRH antagonist, clinically validated for the treatment of endometriosis and fibroids; at a 200-mg dose, it induces profound gonadotropin suppression. However, its efficacy in preventing premature ovulation during COS has not been established. Study design, size, duration This retrospective, monocentric, case–control study was conducted at the Fertility Center of IRCCS San Raffaele Hospital, Milan, between January 2019 and December 2025. All IVF/ICSI cycles performed were eligible for inclusion. Patients were classified into two groups according to the ovulation suppression strategy adopted: Linzagolix 200 mg (cases) or standard injectable GnRH antagonist (Ganirelix; controls). A 1:3 matching was applied for recombinant FSH preparation and starting dose, LH supplementation, age, and BMI. Participants/materials, setting, methods This study included 108 patients undergoing IVF/ICSI cycles. In both groups, antagonists were administered using flexible protocol (follicle size ≥13 mm and estradiol levels ≥400 pg/mL). Patients provided written informed consent for off-label use of Linzagolix. Premature ovulation was assessed using serum progesterone levels ≥3 ng/mL. Progesterone levels on trigger day were evaluated to assess eligibility for fresh embryo-transfer, using a cut-off of ≥ 1.1 ng/mL, corresponding to our threshold for elective freeze-all. Main results and the role of chance No premature ovulation was observed in either group. The rate of premature progesterone elevation ≥1.1 ng/mL was comparable between Linzagolix and control group (33.30% vs 28.40%; p = 0.63). Progesterone concentrations on trigger day showed overlapping distributions, with median values of 0.90 [0.54–1.29] ng/mL in Linzagolix group and 0.67 [0.48–1.21] ng/mL in controls (p = 0.46). Similarly, estradiol levels did not show relevant variation between groups (1637.00 [875.25–2299.75] vs 1904.00 [1209.50–2399.75] pg/mL; p = 0.33). Stimulation duration did not differ between groups, with median lengths of 10.00 [8.50–11.50] and 9.00 [9.00–11.00] days, respectively (p = 0.18). The median number of oocytes retrieved was 9.00 [4.50–12.00] in the Linzagolix group and 8.00 [5.00–12.00] in controls (p = 0.92), with no differences observed in the number of mature (MII) oocytes (6.00 [3.50–8.50] vs 5.00 [3.00–8.00]; p = 0.41). No cycle cancellations occurred in the control group, while one cancellation was reported among Linzagolix-treated cycles (3.70%; p = 0.25). Limitations, reasons for caution This study is limited by its retrospective, monocentric design and the relatively small sample size. Although a matching strategy was applied, residual confounding cannot be excluded. Larger, prospective, randomized studies are needed to validate the results and their clinical implications. Wider implications of the findings These findings suggest that oral ovulation suppression with Linzagolix may represent a practical alternative to injectable GnRH antagonists during COS. Oral administration and potentially lower costs may improve patient acceptability and adherence, supporting further investigation of Linzagolix use within ovarian stimulation protocols for IVF. Trial registration number No

Zitieren

APA

Grisafi, G., Bortolini, B., Molgora, M., Biancardi, R., Privitera, L., Villanacci, R., Alessandro, S. D., Angelini, E., & Papaleo, E. (2026). L26/P-761 Oral Linzagolix for ovulation suppression during controlled ovarian stimulation compared with standard injectable GnRH antagonists in IVF cycles: a retrospective matched case–control study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1088

Vancouver

Grisafi G, Bortolini B, Molgora M, Biancardi R, Privitera L, Villanacci R, et al. L26/P-761 Oral Linzagolix for ovulation suppression during controlled ovarian stimulation compared with standard injectable GnRH antagonists in IVF cycles: a retrospective matched case–control study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1088

BibTeX
@article{Grisafi2026,
  author = {Grisafi, G. and Bortolini, B. and Molgora, M. and Biancardi, R. and Privitera, L. and Villanacci, R. and Alessandro, S. D’ and Angelini, E. and Papaleo, E.},
  title = {L26/P-761 Oral Linzagolix for ovulation suppression during controlled ovarian stimulation compared with standard injectable GnRH antagonists in IVF cycles: a retrospective matched case–control study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1088}
}
Kostenlos starten →